A
A. John Rush
Researcher at Duke University
Publications - 58
Citations - 1546
A. John Rush is an academic researcher from Duke University. The author has contributed to research in topics: Major depressive disorder & Escitalopram. The author has an hindex of 19, co-authored 58 publications receiving 925 citations. Previous affiliations of A. John Rush include Texas Tech University & Harvard University.
Papers
More filters
Journal ArticleDOI
Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity
Madhukar H. Trivedi,David W. Morris,Stephen R. Wisniewski,Ira M. Lesser,Andrew A. Nierenberg,Ella J. Daly,Benji T. Kurian,Bradley N. Gaynes,Goundappa K. Balasubramani,A. John Rush +9 more
TL;DR: Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity, implying a need for additional, possibly novel, treatments.
Journal ArticleDOI
Bupropion and Naltrexone in Methamphetamine Use Disorder
Madhukar H. Trivedi,Robrina Walker,Walter Ling,Adriane M. dela Cruz,Gaurav Sharma,Thomas Carmody,Udi E. Ghitza,Aimee Wahle,Mora Kim,Kathy Shores-Wilson,Steven Sparenborg,Phillip O. Coffin,Joy M. Schmitz,Katharina Wiest,Gavin Bart,Susan C. Sonne,Sidarth Wakhlu,A. John Rush,A. John Rush,A. John Rush,Edward V. Nunes,Steven Shoptaw +21 more
TL;DR: In this article, the use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied and a multisite, double-blind, two-stage, placebo-contr...
Journal ArticleDOI
Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study.
TL;DR: Combining rTMS and PT resulted in a 66% response and a 56% remission rate at the end of treatment with 60% sustained remission at follow-up, compared to previous findings in RCTs.
Journal ArticleDOI
Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial
S. Susan Hedayati,S. Susan Hedayati,L. Parker Gregg,L. Parker Gregg,Thomas J. Carmody,Nishank Jain,Nishank Jain,Marisa Toups,A. John Rush,Robert D. Toto,Madhukar H. Trivedi +10 more
TL;DR: Among patients with non–dialysis-dependent CKD and MDD, treatment with sertraline compared with placebo for 12 weeks did not significantly improve depressive symptoms, and these findings do not support the use of sERTraline to treat MDD in patients withNon– Dialysis- dependent CKD.
Journal ArticleDOI
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.
John Zajecka,David L. Dunner,Alan J. Gelenberg,Robert M. A. Hirschfeld,Susan G. Kornstein,Philip T. Ninan,A. John Rush,Michael E. Thase,Madhukar H. Trivedi,Bruce A. Arnow,Frances E. Borian,Rachel Manber,Martin B. Keller +12 more
TL;DR: Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment.